About
IL-2 Therapies
Areas of Focus
Categories
Biologics & BiopharmaceuticalBiotech
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
982
By Phase
PHASE1: 3
By Status
RECRUITING: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT07037758Collaborator
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
PHASE1Recruiting
380 participants
Started: Sep 16, 2025 · Completed: Jan 4, 2031
NCT07027488Collaborator
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
PHASE1Recruiting
50 participants
Started: Aug 5, 2025 · Completed: Aug 31, 2027
NCT05653882Lead Sponsor
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
PHASE1Active, not recruiting
552 participants
Started: Jan 4, 2023 · Completed: May 31, 2027
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...